These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18663761)

  • 21. Implementing type I & type II error spending for two-sided group sequential designs.
    Rudser KD; Emerson SS
    Contemp Clin Trials; 2008 May; 29(3):351-8. PubMed ID: 17933592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases.
    van der Lee JH; Wesseling J; Tanck MW; Offringa M
    J Clin Epidemiol; 2008 Apr; 61(4):324-30. PubMed ID: 18313556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sample size for two-stage studies with maintenance therapy.
    Feng W; Wahed AS
    Stat Med; 2009 Jul; 28(15):2028-41. PubMed ID: 19382105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discussion of the "White Paper of the PhRMA PISC Working Group on adaptive dose-ranging designs".
    Leonov S
    J Biopharm Stat; 2007; 17(6):1013-4; discussion 1029-32. PubMed ID: 18027211
    [No Abstract]   [Full Text] [Related]  

  • 25. Some challenges with statistical inference in adaptive designs.
    Hung HM; Wang SJ; Yang P
    J Biopharm Stat; 2014; 24(5):1059-72. PubMed ID: 24915027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical trials and rare diseases.
    Gerss JW; Köpcke W
    Adv Exp Med Biol; 2010; 686():173-90. PubMed ID: 20824446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Testing and estimation in flexible group sequential designs with adaptive treatment selection.
    Posch M; Koenig F; Branson M; Brannath W; Dunger-Baldauf C; Bauer P
    Stat Med; 2005 Dec; 24(24):3697-714. PubMed ID: 16320264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnosing model diagnostics.
    Karlsson MO; Savic RM
    Clin Pharmacol Ther; 2007 Jul; 82(1):17-20. PubMed ID: 17571070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discussion of the "White Paper of the PhRMA Working Group on adaptive dose-ranging designs".
    Grieve AP
    J Biopharm Stat; 2007; 17(6):997-1004; discussion 1029-32. PubMed ID: 18027209
    [No Abstract]   [Full Text] [Related]  

  • 30. Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.
    Bauer P; Bretz F; Dragalin V; König F; Wassmer G
    Stat Med; 2016 Feb; 35(3):325-47. PubMed ID: 25778935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perspectives on the use of adaptive designs in clinical trials. Part II. Panel discussion.
    Benda N; Brannath W; Bretz F; Burger HU; Friede T; Maurer W; Wang SJ
    J Biopharm Stat; 2010 Nov; 20(6):1098-112. PubMed ID: 21058105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discussion of the paper "Adaptive dose-ranging designs".
    Burman CF
    J Biopharm Stat; 2007; 17(6):1005-11; discussion 1029-32. PubMed ID: 18027210
    [No Abstract]   [Full Text] [Related]  

  • 33. Discussion of "The White Paper of the PhRMA Working Group on adaptive dose-ranging designs".
    Hemmings R
    J Biopharm Stat; 2007; 17(6):1021-7; discussion 1029-32. PubMed ID: 18027213
    [No Abstract]   [Full Text] [Related]  

  • 34. Perspectives on the use of adaptive designs in clinical trials. Part I. Statistical considerations and issues.
    Wang SJ
    J Biopharm Stat; 2010 Nov; 20(6):1090-7. PubMed ID: 21058104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A group sequential approach to evaluation of bridging studies.
    Hsiao CF; Xu JZ; Liu JP
    J Biopharm Stat; 2003 Nov; 13(4):793-801. PubMed ID: 14584723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of methods for adaptive treatment selection.
    Friede T; Stallard N
    Biom J; 2008 Oct; 50(5):767-81. PubMed ID: 18932136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and of classical group sequential approaches.
    Müller HH; Schäfer H
    Biometrics; 2001 Sep; 57(3):886-91. PubMed ID: 11550941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A computationally simpler algorithm for the UMVUE of a normal mean following a group sequential trial.
    Emerson SS; Kittelson JM
    Biometrics; 1997 Mar; 53(1):365-9. PubMed ID: 9147601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An introduction to latent growth curve modelling for longitudinal continuous data in dental research.
    Tu YK; D'Aiuto F; Baelum V; Gilthorpe MS
    Eur J Oral Sci; 2009 Aug; 117(4):343-50. PubMed ID: 19627343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An overview of group sequential methods in longitudinal clinical trials.
    Spiessens B; Lesaffre E; Verbeke G; Kim K; DeMets DL
    Stat Methods Med Res; 2000 Oct; 9(5):497-515. PubMed ID: 11191262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.